DLBCL
Conditions
Interventions
experimental group:Rituximab combined with lenalidomide, etoposide, methotrexate, vincristine, adriamycin, cyclophosphamide, prednisone
Sponsors
The Affiliated Hospital of Xuzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. The first diagnosis of CD5 + DLBCL (except primary mediastinal large B-cell lymphoma, primary central lymphoma, HIV related lymphoma) confirmed by pathological tissue, the diagnosis standard is in accordance with who 2008. 2. Aged <= 70 years with ECoG PS <= 2 points; 3. The expected service life is more than 3 months; 4. Ann Arbor stage I-IV; 5. There are follow-up conditions. The patients knew the characteristics of the disease, and voluntarily joined the study program for treatment and follow-up.
Exclusion criteria
Exclusion criteria: 1. The patients with abnormal liver and kidney function, specifically the direct bilirubin, indirect bilirubin and / or alanine aminotransferase, glutamic oxaloacetylase, serum creatinine > 2 * normal value, unless the abnormal liver and kidney function is identified as related to lymphoma; 2. In patients with bone marrow failure, the specific definition is absolute neutrophil count (ANC) 1 * 10^4 copies / ml) and hepatitis C patients; 6. Lymphoma has been proved to involve the central nervous system; 7. Other malignant tumors other than lymphoma are diagnosed or under treatment, except for the following: (1) It has been treated for the purpose of cure, and there was no known active disease of malignant tumor at least 5 years before the group was enrolled; (2) Basal cell carcinoma of the skin (excluding melanoma) that has been treated well and shows no signs of disease; (3) Cervical carcinoma in situ, which has been fully treated and shows no signs of disease. 8. At the same time, they have other blood system diseases (such as hemophilia, myelofibrosis, etc.), which the researchers think are not suitable for the candidates; 9. Serious infection; 10. The patients were operated on at least level 2 within 3 weeks before the treatment; 11. Drug abuse, medical, psychological or social conditions that may interfere with subjects' participation in the study or evaluation of the results of the study; 12. The researchers think it is not suitable for the participants; 13. Those who are known to be allergic to the ingredients of the test drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CRR; | — |
Secondary
| Measure | Time frame |
|---|---|
| ORR;OS;PFS; | — |
Countries
China
Contacts
Public ContactWei Sang
The Affiliated Hospital of Xuzhou Medical University
Outcome results
None listed